A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
NCT ID: NCT06164730
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
85 participants
INTERVENTIONAL
2024-04-30
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Single Ascending Dose Escalation
Participants will receive a single dose of VERVE-102.
VERVE-102
Intravenous (IV) infusion
Cohort 2: Single Ascending Dose Escalation
Participants will receive a single dose of VERVE-102.
VERVE-102
Intravenous (IV) infusion
Cohort 3: Single Ascending Dose Escalation
Participants will receive a single dose of VERVE-102.
VERVE-102
Intravenous (IV) infusion
Cohort 4: Single Ascending Dose Escalation
Participants will receive a single dose of VERVE-102.
VERVE-102
Intravenous (IV) infusion
Cohort 5: Single Ascending Dose Escalation
Participants will receive a single dose of VERVE-102.
VERVE-102
Intravenous (IV) infusion
Cohort 6: Single Ascending Dose Escalation
Participants will receive a single dose of VERVE-102.
VERVE-102
Intravenous (IV) infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VERVE-102
Intravenous (IV) infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Active or history of chronic liver disease
* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
* Clinically significant or abnormal laboratory values as defined by the protocol
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Verve Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Study Center
Dothan, Alabama, United States
Clinical Study Center
Adelaide, , Australia
Clinical Study Center
Melbourne, , Australia
Clinical Study Center
Sydney, , Australia
Clinical Study Center
Chicoutimi, , Canada
Clinical Study Center
Montreal, , Canada
Clinical Study Center
Toronto, , Canada
Clinical Study Center
Vancouver, , Canada
Clinical Study Center
Rehovot, , Israel
Clinical Study Center
Christchurch, , New Zealand
Clinical Study Center
Birmingham, , United Kingdom
Clinical Study Center
Edinburgh, , United Kingdom
Clinical Study Center
London, , United Kingdom
Clinical Study Center
Manchester, , United Kingdom
Clinical Study Center
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VT-10201
Identifier Type: -
Identifier Source: org_study_id